Onco-Hu® Models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells to help destroy cancers in vivo.
Human CD34+ hematopoietic stem cell-engrafted NSG™ mice (hu-CD34) develop multi-lineage human immune cells, and are a validated platform for immuno-oncology efficacy studies, and infectious disease research. Our inventory has CD34+ mice available for immediate shipment to your facility or efficacy study enrollment at ours.
Female mice are injected with human hematopoietic stem cells (hu-CD34+). Engraftment of mature human white blood cells (hCD45+) is confirmed 16 weeks after injection. Any mouse with more than 25% hCD45+ cells is considered successfully humanized.
Hu-CD34-NSG™ and hu-CD34-SGM3 are ideal for long-term in vivo studies in the areas of immuno-oncology, infectious diseases and graft rejection research -since their lifespan after CD34+ engraftment is over 12 months.
These preclinical models are also used as platforms for screening efficacy of genetically modified stem cells (Kitchen et al. 2012).
Study-ready cohorts of inventoried humanized CD34+ mice are readily available for shipment to your institution or for enrollment in customized drug efficacy studies executed by our experienced Ph.D. level scientists from JAX In Vivo Services.
Director, Technology Transfer
The Jackson Laboratory